elanur karaman - Academia.edu (original) (raw)

Papers by elanur karaman

Journal of Cancer Research and Therapeutics, Sep 24, 2022

Eurasian Journal of Medical Investigation

G astric cancer, which is the second most common gastrointestinal system tumor, is the third most... more G astric cancer, which is the second most common gastrointestinal system tumor, is the third most common cause of cancer-related deaths in the World. [1] Because the disease is asymptomatic until advanced stages and there are no active widespread screening programs, most of the patients can be diagnosed in advanced stages. Stage, performance status and comorbidities, tumor histology, pathology, localization and surgical methods affect the prognosis. [2,3] In addition, Hemoglobin, Albumin, Lymphocyte, and Platelet Score (HALP) and metastatic lymph node ratio Objectives: The main treatment for gastric cancer is surgery. The high recurrence and metastasis rates indicate the necessity of neoadjuvant/adjuvant treatments. Our aim was to evaluate the effects of adjuvant therapy on disease-free survival (DFS) and prognostic factors with gastric cancer patients. Methods: Gastric cancer patients who were operated between 2015-2021 were evaluated retrospectively. Clinical, pathological, surgical and therapeutic features of patients were examined. Prognostic factors, Hemoglobin Albumin Lymphocyte, Platelet Score (HALP) and metastatic lymph node ratio (MLNR) of patients were examined. 1-5 year survival rate were calculated. Results: Adjuvant chemotherapy was applied to fifty-nine patients and adjuvant chemoradiotherapy was applied to sixtyeight patients. There was no difference in demographic and clinical characteristics between patient groups who received chemotherapy and chemoradiotherapy. DFS was 34 and 52 months with chemotherapy and chemoradiotherapy patients respectively (p=0.161). High MLNR levels of patients was poor prognostic factor. HALP score did not affect prognosis. 5-years overall survival rate was better in chemoradiotherapy group, but the difference was not statistically significant (41.2% vs 50.9%, p=0.216). Conclusion: There was no difference in survival between patients who received adjuvant chemotherapy and chemoradiotherapy. MLNR of patients may be considered as a prognostic marker for gastric cancer patients with high nodal involvement.

Cumhuriyet Medical Journal

Lung cancer is frequently seen in patients who smoke, who are elderly, and who have more comorbid... more Lung cancer is frequently seen in patients who smoke, who are elderly, and who have more comorbid diseases. The risk of being affected by the Covid-19 pandemic is high. Here, we aimed to determine the effectiveness of the definitive chemoradiotherapy (CRT) in patients with non metastatic non-small cell lung cancers (NSCLC) during the pandemic period. Patients with NSCLCs, between 2020-2022 were evaluated retrospectively. Treatment responses were evaluated and prognostic factors were investigated. Twenty-eight patients (70%) were men and twelve (30%) were women. Twenty-five (62.5%) patients had comorbidities. All of patients complated their treatments. Objective response rate was 72.5%. Respectively, 72.5% of patients had partial response, 27.5% of patients had stabile disease. 92.5% of patients had a reduction in primary tumor, 42.5% had lymph nodes and 75% had a reduction in stage. Seven (17.5%) patients developed Covid-2019. Passing a Covid-2019 was decreased survival (p=0.012). I...

Cureus

Introduction Cancer patients are among the groups at high risk in the COVID-19 pandemic. Here, we... more Introduction Cancer patients are among the groups at high risk in the COVID-19 pandemic. Here, we aimed to determine the effectiveness of neoadjuvant chemotherapy (NACT) during the pandemic period and examine the prognostic factors in patients with non-small cell lung cancer (NSCLC). Method Patients with stage I-III NSCLC were treated in our hospitals between 2020-2022. Treatment responses were evaluated in patients who underwent NACT. Prognostic factors and the nutritional and inflammatory indexes were investigated. Results Thirty-eight patients received NACT. 57.9% of patients were stage-III. The objective response rate was 57.9%. Pathological complete response was obtained in 10.5% of patients. No prognostic role of inflammatory indices was determined. 21.1% of patients developed a COVID-19 infection. Disease-free survival was 19 months. Survival decreased with large tumor size and presence of metastasis. Conclusion NACT has high response rates. NACT can be used as bridging therapy in suitable patients whose surgery is postponed during the pandemic period.

Revista da Associação Médica Brasileira

OBJECTIVES: Black cumin is widely used as a spice and as a traditional treatment. The active ingr... more OBJECTIVES: Black cumin is widely used as a spice and as a traditional treatment. The active ingredient in black cumin seeds is thymoquinone. Thymoquinone has shown anticancer effects in some cancers. We planned to investigate its anticancer effect on pancreatic cancer cell lines. METHODS: Thymoquinone chemical component in various doses was prepared and inoculated on pancreatic cancer cell culture, healthy mesenchymal stem cells, and peripheral blood mononuclear cell culture. IC50 values were calculated by absorbance data and measuring cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide staining of cells incubated with thymoquinone at 24, 48, and 72 h. RESULTS: There was dose-related cytotoxicity. Maximal cytotoxicity was observed at 24 h and 100 μM thymoquinone concentrations in pancreatic cancer cell culture and mesenchymal stem cells. Any concentration of thymoquinone was not cytotoxic to peripheral blood mononuclear cell. Thymoquinone even caused proliferation at a concentration of 6.25 μM. CONCLUSIONS: Since the cytotoxic concentration of thymoquinone on pancreatic cancer cell culture and mesenchymal stem cells is the same, it is not appropriate to use thymoquinone to achieve cytotoxicity in pancreatic cancer. However, since thymoquinone provides proliferation in peripheral blood mononuclear cell at a noncytotoxic dose, it may have an immune activator effect. Therefore, in vivo studies are needed to investigate the effect of thymoquinone on the immune system.

Journal of the College of Physicians and Surgeons Pakistan

Objective: To evaluate the effect of metabolic tumor volume (MTV) and total lesion glycolysis (TL... more Objective: To evaluate the effect of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) values of the primary tumor measured by preoperative positron emission tomography/computed tomography (FDG-PET/CT) on survival in patients with operated non-small cell lung cancer (NSCLC).

Anti-Cancer Drugs, 2022

Regorafenib is a multikinase inhibitor. It is used for metastatic colorectal cancer (mCRC) treatm... more Regorafenib is a multikinase inhibitor. It is used for metastatic colorectal cancer (mCRC) treatment. It has a mild effect. Regorafenib outcomes, and side effects may vary across patients. This study was aimed to evaluate the factors that affect regorafenib outcomes in mCRC patients. We conducted a single-center and retrospective study. Fifty-six patients were included. All patients had received regorafenib for mCRC. Some clinical and pathological factors and the effects of these factors on overall survival (OS), progression-free survival (PFS), and disease control rates (DCR) were analyzed. Concomitant amlodipine intake with regorafenib improved OS [14.26 vs. 6.97 months; 95% confidence interval, 4.04–20.84; P = 0.031] and DCR at 12th week (90% vs. 46%; P = 0.012). Hepatic metastasis was found as the poorest prognostic factor in both univariate and multivariate analyses. Patients who received chemotherapy after regorafenib had better OS. Good performance status was the strongest indicator of better OS. Patients taking amlodipine for arterial hypertension at the same time with regorafenib had numerically better OS and PFS and statistically better DCR. Amlodipine itself already has anticancer effects, and it has additive anticancer effects with regorafenib. The presence of hepatic metastases was found to be the most important prognostic factor for OS. There were not any predictive factors of side effects to regorafenib.

Eurasian Journal of Medical Investigation, 2022

L ung cancer is the leading cause of cancer-related death in the world. Almost 10-20% of patients... more L ung cancer is the leading cause of cancer-related death in the world. Almost 10-20% of patients have brain metastases at the time of diagnosis. [1] Despite the advancements in diagnosis and treatment, average survival is 15-20 months in the limited stage and decreases to 8-13 months in the extensive stage. Factors including advanced age, male gender, metastatic stage, and poor performance status have adverse effects on survival. [2] In addition, the presence, number, and control status of brain metastases and the presence of liver metastasis have also been shown to adversely affect the survival. [3,4] In the literature, various prognostic scoring systems such as Recursive Partitioning Analysis (RPA), Diagnostic-specific Graded Prognostic Assessment (DS-GPA), Basic Score for Brain Metastases (BSBM), and Brain Metastases Score (BMS-Score) have been used to evaluate the prognosis in patients with brain metastases. [5] Carcinoembryonic antigen (CEA) is a glycoprotein mostly secreted from the gastrointestinal epithelium. [6] In SCLC, 32.8-42.7% of patients have elevated serum CEA levels. Moreover, some studies reported that high CEA levels were associated with negative survival in SCLC with brain me-Objectives: Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Despite advances in technology and treatments there is no desirable improvement in survival. The present study evaluated the factors affecting survival in patients with SCLC. Methods: Patients with SCLC followed up in our clinic between 2019 and 2021 were retrospectively reviewed. Univariate and multivariate analyses were performed to identify the prognostic factors. Kaplan-Meier method was used for survival analysis. Results: The 60 patients comprised 50 (83.3%) men and 10 (16.7%) women with a median age of 61 (53.3-67) years. 40 (66.7%) patients were in extensive stage, 13 (21.7%) patients had brain metastases at the time of diagnosis, and 41 (68.3%) patients had extracranial metastases. There were 18(45%) patients with high serum carcinoembryonic antigen levels and 33 (63%) patients with high lactate dehydrogenase levels at the time of diagnosis. Primer disease control control was achieved in 30 (63%) patients, while Progression developed in 26 (45.6%) patients. Median overall survival was 13 months and it was revealed that survival was better in patients who received ≥4 cycles of chemotherapy, wholebrain radiotherapy, thoracic radiotherapy and disease control. Conclusion: The success of systemic and local treatment was found to be the most important factor affecting survival in patients with SCLC.

A 39 year old woman, who had 3 children, was admitted with complaints of abnormal uterine bleedin... more A 39 year old woman, who had 3 children, was admitted with complaints of abnormal uterine bleeding. Endometrial biopsy was performed and result was found as endometrial adenosarcoma. There were no distant metastases found at imaging. TAH + BSO (Total Abdominal Hysterectomy and Bilateral Salpingo-Oophorectomy) operation was performed and adjuvant chemotheraphy (four cyclus ifosfamide, mesna, epirubicin) was given. We did not encounter any problems in monitoring. This case which includes endometrial adenosarcoma is presented because of its rarity.

Acta gastro-enterologica Belgica, 2020

PURPOSE The prevalence of hepatitis B virus (HBV) reacti- vation in HBsAg-negative/anti-HBc-posit... more PURPOSE The prevalence of hepatitis B virus (HBV) reacti- vation in HBsAg-negative/anti-HBc-positive patients receiving chemotherapy for solid tumors is not fully known. The aim of this study was to investigate the incidence and outcomes of HBV reactivation in these patients. METHODS Data among 645 HBsAg-negative/ anti-HBc-positive patients who underwent intravenous chemotherapy were retrospectively analyzed. Patients were categorized into two groups, based on received antiviral prophylaxis (n = 43) or not (n = 602). HBV reactivation was defined as the presence of detectable serum HBV DNA or HBsAg seroconversion from negative to positive, with or without increased liver enzymes. RESULTS HBV reactivation was detected in 3 patients (0.49%) among non-antiviral prophylaxis group and in none of those with antiviral prophylaxis. Two of the HBV reactivation detected patients were successfully treated with rescue therapy, while the third died due to liver failure. CONCLUSIONS HBV reactivati...

Turkish Journal of Oncology, 2017

Nonepithelial tumors of the prostate represent <1% of all prostate tumors. A rare soft tissue sar... more Nonepithelial tumors of the prostate represent <1% of all prostate tumors. A rare soft tissue sarcoma is common in the lower extremities and can occur anywhere in the body. Malignant mesenchymal tumors of the prostate are rarely observed. The histogenesis of malignant mesenchymal tumors that have totipotential differentiation capacity and arise from primitive mesenchymal cells is still unknown. These are malignant soft tissue sarcomas including ≥2 different mesenchymal elements in addition to the fibrosarcomatous elements. This type of tumors can occur anywhere within the body; the most frequently reported sites are the retroperitoneal cavity and lower extremity. They may occur in the heart, mediastinum, pleura, liver, eyes, bones, larynx, thyroid, testis, uterus, and bladder. The malignant potential is high and the progression of these tumors is rapid. There is mass in the prostate; however, when the prostate-specific antigen levels are normal, differential diagnoses should be considered. Although the main treatment for this disease is surgery, chemotherapy and/or radiotherapy can be applied. We present a rare case of malignant mesenchymal tumor of the prostate.

Indian Journal of Palliative Care, 2019

Background: Art, as a product of human behavior, is the expression of emotions from inner states ... more Background: Art, as a product of human behavior, is the expression of emotions from inner states and may provide catharsis, purification, and release. Several branches of art, most notably music, dance, and painting, can be used for treatment purposes, especially in the case of psychological disorders. Cancer, which is defined as uncontrolled cell growth, has been an important health issue throughout history, but the recent increase in its frequency has made it one of the most significant public health problems. Both the physiological distress the disease subjects the body to and the accompanying emotional distress are important factors to be considered in cancer treatment. Aims: In this study, the role of art in expressing emotions of oncological patients was investigated. Materials and Methods: During the treatment period, patients were interviewed about their experiences, feelings, expectations and perceptions. The picture was used as an expression of emotions. Results: Communication between the patient and doctor is one of the most important elements in the treatment process, and it has come to the fore in branches of medicine, such as oncology, because of its positive contribution to treatment compliance. In general, the study showed a pronounced positivity and expectations on the part of patients from the hope-life-healing process rather than oncological treatment. Conclusion: In this study, we aim to demonstrate how the artistic expression of emotions, in particular, through painting, has a positive effect on healing, hope, and the interactions between cancer patients under oncological treatment and medical professionals.

International Journal of Scientific and Technological Research, 2019

Gut arthritisis is an acute inflammatory arthritis characterized by pain and storing of monosodiu... more Gut arthritisis is an acute inflammatory arthritis characterized by pain and storing of monosodium urate crystals in joints or tissues. In our study we aim to increase awareness of patients with gout arthritis. It was evaluated the demographic, clinical and laboratory features of 118 patients with acute gout arthritis who admitted to the